Prevention of hepatocellular carcinoma in chronic liver disease: Molecular markers and clinical implications

被引:1
|
作者
Plesch, FN [1 ]
Kubicka, S [1 ]
Manns, MP [1 ]
机构
[1] Hannover Med Sch, Dept Gastroenterol & Hepatol, D-30625 Hannover, Germany
关键词
hepatocellular carcinoma; prevention; screening; adjuvant therapy; molecular marker;
D O I
10.1159/000050701
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The development of hepatocellular carcinoma is generally preceded by chronic liver damage leading to cirrhosis. Prevention of chronic liver diseases can decrease the incidence of hepatic cancer impressively. Many recent investigations have also explored the power of secondary and tertiary prevention in established liver cirrhosis. Screening programs for patients at high risk, antiviral treatment of patients with progressed hepatitis, and adjuvant interventions after curative resection are some of the approaches. However, the cost effectiveness and benefits of such procedures and the prognosis is also dependent on the remaining liver function, there is no consensus to date on how patients should be handled. In the future molecular markers and prognostic scores may help better define the group at risk of developing. To give a perspective to these patients, it is necessary to improve the treatment of hepatocellular carcinoma as well as cirrhosis. Copyright (C) 2002 S. Karger AG, Basel.
引用
收藏
页码:338 / 344
页数:7
相关论文
共 50 条
  • [1] Progression of chronic liver disease to hepatocellular carcinoma: implications for surveillance and management
    Philip J. Johnson
    Anton Kalyuzhnyy
    Ellen Boswell
    Hidenori Toyoda
    BJC Reports, 2 (1):
  • [2] Fibro markers for prediction of hepatocellular carcinoma in Egyptian patients with chronic liver disease
    Mobarak, Lamiaa
    Omran, Dalia
    Nabeel, Mohammed M.
    Zakaria, Zeinab
    JOURNAL OF MEDICAL VIROLOGY, 2017, 89 (06) : 1062 - 1068
  • [3] The Molecular Pathogenesis and Clinical Implications of Hepatocellular Carcinoma
    Meguro, Makoto
    Mizuguchi, Toru
    Kawamoto, Masaki
    Hirata, Koichi
    INTERNATIONAL JOURNAL OF HEPATOLOGY, 2011, 2011
  • [4] Screening for Hepatocellular Carcinoma in Chronic Liver Disease
    Giannini, Edoardo G.
    Trevisani, Franco
    ANNALS OF INTERNAL MEDICINE, 2015, 162 (03) : 239 - 240
  • [5] Sirolimus and liver transplantation: clinical implications for hepatocellular carcinoma
    Campsen, Jeffrey
    Zimmerman, Michael A.
    Trotter, James F.
    Wachs, Michael
    Bak, Thomas
    Mandell, Susan
    Kam, Igal
    EXPERT OPINION ON PHARMACOTHERAPY, 2007, 8 (09) : 1275 - 1282
  • [6] BIOLOGICAL MARKERS IN HEPATOCELLULAR-CARCINOMA - POTENTIAL CLINICAL IMPLICATIONS
    SILVESTRINI, R
    COSTA, A
    DERRICO, A
    FARANDA, A
    REGALIA, E
    GRIGIONI, W
    GENNARI, L
    JOURNAL OF SURGICAL ONCOLOGY, 1993, : 18 - 20
  • [7] Telomerase in hepatocellular carcinoma, metastatic carcinoma and chronic liver disease
    Li, HM
    Wu, S
    Liew, CT
    Loew, CK
    Lau, JWY
    Lim, BK
    Wang, XQ
    Chan, JYH
    Lee, JCK
    HEPATOLOGY, 1997, 26 (04) : 1307 - 1307
  • [8] Molecular diagnosis of chronic liver disease and hepatocellular carcinoma: The potential of gene expression profiling
    Lemmer, Eric R.
    Friedman, Scott L.
    Llovet, Josep M.
    SEMINARS IN LIVER DISEASE, 2006, 26 (04) : 373 - 384
  • [9] Chromogranin A levels in chronic liver disease and hepatocellular carcinoma
    Massironi, S.
    Fraquelli, M.
    Paggi, S.
    Sangiovanni, A.
    Conte, D.
    Sciola, V.
    Ciafardini, C.
    Colombo, M.
    Peracchi, M.
    DIGESTIVE AND LIVER DISEASE, 2009, 41 (01) : 31 - 35
  • [10] Screening for Hepatocellular Carcinoma in Chronic Liver Disease RESPONSE
    Kansagara, Devan
    Papak, Joel
    Jou, Janice H.
    ANNALS OF INTERNAL MEDICINE, 2015, 162 (03) : 240 - 240